An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3- Oxo-1H-1,4-benzodiazepine-2-acetate

Tetrahedron Letters

Volumn 38, Issue 18, 1997, Pages 3131-3134

  Thomas, W Ku ^a   Fadia, E Ali ^a   Bondinell, William E ^a   Erhard, Karl F ^a   Huffman, William F ^a   Venslavsky, Joseph W ^a   Yuan, Catherine C K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 TERT BUTOXYCARBONYL 2,3,4,5 TETRAHYDRO 4 METHYL 3 OXO 1H 1,4 BENZODIAZEPINE 2 ACETATE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DRUG SYNTHESIS; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; REACTION ANALYSIS; STEREOCHEMISTRY;

EID: 0342601509     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(97)00570-4     Document Type: Article

References (21)

1. Coller, B. S. N. Engl. J. Med. 1990, 322, 33-42.
2. Phillips, D. R.; Charo, I. F.; Panse, L. V.; Fitzgerald, L. A. Blood 1988, 71, 831-843.
3. Pierschbacher, M. D.; Ruoslahti, E. Nature 1984, 309, 30-33.
4. Plow, E. F.; Ginsberg, M.; Marguerie, G. A. In Biochemistry of Platelets; D. R. Phillips and M. R. Shuman, Ed.; Academic Press: New York, 1986; pp 226-251.
5. Gartner, T. K.; Bennett, J. S. J. Biol. Chem. 1985, 260, 11891-11894.
6. Strony, J.; Adelman, B.; Phillips, D. R.; Scarborough, R. M.; Charo, I. F. Circulation 1991, 84 (October Suppl.), 0985a.
7. For recent reviews on fibrinogen receptor antagonists, see a) Samanen, J. Ann. Rep. Med. Chem. 1996, 31, 91 - 100.
8. b) Ojima, I.; Chakravarty, S.; Dong, Q., Bioorg. & Med. Chem., 1995, 3, 337-360.
9. (c) Nichols, A. J.; Vasko, J. A.; Koster, P. F.; Valocik, R. E.; Samanen, J. M. in Cellular Adhesion: Molecular Definition to Therapeutic Potential; Metcalf, B. W., Dalton, B. J., Poste, G., Eds.; Plenum Press: New York, 1994; p. 213 - 237.
10. (d) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Drugs of the Future 1994, 19, 135 - 159.
11. e) Nichols, A. J.; Ruffolo, R. R., Jr.; Huffman, W. F.; Poste, G.; Samanen, J. Trends in Pharmaceutical Sciences 1992, 13, 413 - 417.
12. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S.-M.; Jakas, D.R; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. J. Am. Chem. Soc. 1993, 115, 8861 - 8862.
13. Ali, F. E.;. Bennett, D. B.; Calvo, R. R.; Elliott, J. D.; Hwang, S. M.;. Ku, T. W.; Lago, M. A.; Nichols, A. J.; Romoff, T. T.; Shah, D. H.; Vasko, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C. -K.; Samanen, J. M. J. Med. Chem. 1994, 37, 769-780.
14. Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Erhard, K. F.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Huffman, W. F. J. Med. Chem. 1995, 38, 9 - 12.
15. Samanen, J.; Ali, F. E.; Barton, L.; Bondinell, W.; Burgess, J.; Callahan, J.; Calvo, R.; Chen, L.; Chen, K.; Erhard, K.; Heyes, R.; Hwang, S.-M.; Jakas, D.; Keenan, R.; Ku, T.; Kwon, C.; Lee, C.-P.; Miller, W.; Newlander, K.; Nichols, A.; Peishoff, C.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzinskas, I.; Venslavsky, J.; Wong, A.; Yuan, C.-K.; Huffman, W. In The Proceedings of the 14th American Peptide Symposium (Peptides: Chemistry, Structure and Biology); Kaumaya, P. T. P., Hodges, R. S., Eds.; Escom: Leiden, Mayflower Scientific, 1996, 670-681.
16. Miller, W. H., Ku, T. W., Ali, F. E., Bondinell, W. E., Calvo, R. R., Davis, L. D., Erhard, K. F., Hall, L. B. Huffman, W. F., Keenan, R. M., Kwon, C. Newlander, K. A., Ross, S. T., Samanen, J. M., Takata, D. T., and Yuan, C. -K. Tetrahedron. Lett. 1995, 36, 9433-9436.
17. Muller, W. and Stauss, U., Helv. Chim. Acta. 1982, 65, 2118-2132.
18. b) Bondinell, W. E.; Callahan, J. F.; Huffman, W. F.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Samanen, J. M.; Uzinskas, I. N. WO 9414776 (7 July 1994).
19. All new compounds gave satisfactory spectroscopic and analytical data.
20. R (S) = 19.1 min.
21. Although the three-step transformation is a relatively simple process, 12 must be desalted through a XAD-2 column. The resulting lyophilized powder is difficult to dry, which may contribute to a lower-than-expected yield in the final cyclization step.